Table 1.
Clinical characteristics of 62 patients
| Variables | N (%) |
|---|---|
| Gender | |
| Male | 54 (87.1) |
| Female | 8 (12.9) |
| Age (years) | |
| Median (range) | 60.5 (40–72) |
| >60 | 32 (51.6) |
| ≤60 | 30 (48.4) |
| PS | |
| 0–1 | 52 (83.9) |
| 2 | 10 (16.1) |
| Smoking history | |
| Yes | 46 (74.2) |
| No | 16 (25.8) |
| Alcohol use | |
| Yes | 49 (79.0) |
| No | 13 (21.0) |
| Location of tumor | |
| Upper third | 9 (14.5) |
| Middle third | 24 (38.7) |
| Lower third | 29 (46.8) |
| Line of apatinib therapy | |
| Second | 21 (33.9) |
| Further | 41 (66.1) |
| Prior therapies in advanced stage | |
| Chemotherapy | 44 (71.0) |
| Chemoradiotherapy | 18 (29.0) |
| Post-progression therapy after apatinib | |
| Chemotherapy | 16 (25.8) |
| Palliative treatment | 46 (74.2) |
Abbreviation: PS, performance status.